Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections

Journal of Clinical Microbiology

Volumn 44, Issue 10, 2006, Pages 3562-3568

  Saito, Hidetsugu ^a   Tada, Shinichiro ^a   Ebinuma, Hirotoshi ^a   Ishii, Hiromasa ^a   Kashiwazaki, Kazuo ^b   Takahashi, Masahiko ^c   Tsukada, Nobuhiro ^d   Nishida, Jiro ^e   Tanaka, Shin ^f   Shiozaki, Hiroshi ^g   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^c TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^d SAISEIKAI CENTRAL HOSPITAL   (Japan)

^e Tokyo Dental College   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^g Tochigi Saisei kai Utsunomiya Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HEMOGLOBIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANEMIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG UPTAKE; DRUG WITHDRAWAL; ERYTHROCYTE; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; INSOMNIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RETINOPATHY; SKIN PRURITUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; AGED; DOSE RESPONSE; METABOLISM; MIDDLE AGED;

HEPATITIS C VIRUS;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 33947322237     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00079-06     Document Type: Article

References (48)

1. Ahmed, A., and E. B. Keeffe. 1999. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J. Gastroenterol. Hepatol. 14(Suppl.):S12-S18.
2. Alberti, A., and L. Benvegnu. 2003. Management of hepatitis C. J. Hepatol. 38(Suppl. 1):S104-S118.
3. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, J. Albrecht, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
4. De Franceschi, L., G. Fattovich, F. Turrini, K. Ayi, C. Brugnara, F. Manzato, F. Noventa, A. M. Stanzial, P. Solero, and R. Corrocher. 2000. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31:997-1004.
5. Ebinuma, H., H. Saito, S. Tada, T. Masuda, T. Kamiya, J. Nishida, M. Yoshioka, and H. Ishii. 2004. Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-beta treatment for chronic hepatitis C. Hepatogastroenterology 51:1109-1114.
6. Fernandez, H., G. Banks, and R. Smith. 1986. Ribavirin: a clinical overview. Eur. J. Epidemiol. 2:1-14.
7. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
8. Goudou, K., S. Enoki, A. Tsubota, and H. Kumada. 2002. Establishment of the assay for ribavirin in human serum by high-performance liquid chromatography with column-switching. Igaku Yakugaku 47:317-320.
9. Helbling, B., I. Stamenic, F. Viani, J. J. Gonvers, J. F. Dufour, J. Reichen, G. Cathomas, M. Steuerwald, J. Borovicka, M. Sagmeister, and E. L. Renner. 2002. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 35:447-454.
10. Hepatology. 1997. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26(3 Suppl. 1):2S-10S.
11. Homma, M., Y. Matsuzaki, Y. Inoue, M. Shibata, K. Mitamura, N. Tanaka, and Y. Kohda. 2004. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin. Gastroenterol. Hepatol. 2:337-339.
12. Hoofnagle, J. H. 1997. Hepatitis C: the clinical spectrum of disease. Hepatology 26:15S-20S.
13. Ichida, F., T. Tsuji, M. Omata, T. Ichida, K. Inoue, T. Kamimura, G. Yamada, K. Hino, O. Yokosuka, and H. Suzuki. 1996. New Inuyama classification new criteria for histological assessment of chronic hepatitis. Int. Hepatol. Commun. 6:112-119.
14. Jarvis, S. M., J. A. Thorn, and P. Glue. 1998. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J. Pharmacol. 123:1587-1592.
15. Jen, J. F., P. Glue, S. Gupta, D. Zambas, and G. Hajian. 2000. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther. Drug Monit. 22:555-565.
16. Kamar, N., E. Chatelut, E. Manolis, T. Lafont, J. Izopet, and L. Rostaing. 2004. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am. J. Kidney Dis. 43:140-146.
17. Kasahara, A. 2000. Treatment strategies for chronic hepatitis C virus infection. J. Gastroenterol. 35:411-423.
18. Kasahara, A., N. Hayashi, K. Mochizuki, M. Oshita, K. Katayama, M. Kato, M. Masuzawa, H. Yoshihara, M. Naito, T. Miyamoto, A. Inoue, A. Asai, T. Hijioka, H. Fusamoto, and T. Kamada. 1997. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J. Hepatol. 26:574-583.
19. Larrat, S., F. Stanke-Labesque, A. Plages, J. P. Zarski, G. Bessard, and C. Souvignet. 2003. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob. Agents Chemother. 47:124-129.
20. Lindahl, K., R. Schvarcz, A. Bruchfeld, and L. Stahle. 2004. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J. Viral Hepat. 11:84-87.
21. Maddrey, W. C. 1999. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin. Liver Dis. 19(Suppl. 1):67-75.
22. Mangia, A., R. Santoro, M. Piattelli, G. Leandro, N. Minerva, M. Annese, D. Bacca, F. Spirito, V. Carretta, F. Ventrella, M. Cela, and A. Andriulli. 2002. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J. Hepatol. 37:109-116.
23. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
24. Marinosci, F., C. Bergamini, E. Fransvea, N. Napoli, P. Maurel, P. Dentico, S. Antonaci, and G. Giannelli. 2005. Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin. J. Interferon Cytokine Res. 25:453-458.
25. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, J. K. Albrecht, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485- 1492.
26. McHutchison, J. G., M. Manns, K. Patel, T. Poynard, K. L. Lindsay, C. Trepo, J. Dienstag, W. M. Lee, C. Mak, J.-J. Garaud, J. K. Albrecht, and the International Hepatitis Interventional Therapy Group. 2002. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061-1069.
27. Ninomiya, T., S. Yoon, H. Nagano, Y. Kumon, Y. Seo, M. Kasuga, Y. Yano, M. Nakaji, and Y. Hayashi. 2001. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients. Intervirology 44:227-231.
28. Okamoto, H., K. Kurai, S. Okada, K. Yamamoto, H. Lizuka, T. Tanaka, S. Fukuda, F. Tsuda, and S. Mishiro. 1992. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology 188:331-341.
29. Page, T., and J. D. Connor. 1990. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22:379-383.
30. Patil, S. D., L. Y. Ngo, P. Glue, and J. D. Unadkat. 1998. Intestinal absorption of ribavirin is preferentially mediated by the Na-nucleoside purine (N1) transporter. Pharm. Res. 15:950-952.
31. Pol, S., P. Couzigou, M. Bourliere, A. Abergel, J. M. Combis, D. Larrey, A. Tran, J. Moussalli, R. Poupon, P. Berthelot, and C. Brechot. 1999. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J. Hepatol. 31:1-7.
32. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, J. Albrecht, et al. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
33. Poynard, T., J. McHutchison, G. L. Davis, R. Esteban-Mur, Z. Goodman, P. Bedossa, and J. Albrecht. 2000. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131-1137.
34. Poynard, T., J. McHutchison, M. Manns, C. Trepo, K. Lindsay, Z. Goodman, M. H. Ling, and J. Albrecht. 2002. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313.
35. Saito, H., H. Ebinuma, H. Nagata, Y. Inagaki, Y. Saito, K. Wakabayashi, T. Takagi, M. Nakamura, H. Katsura, Y. Oguchi, and H. Ishii. 2001. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver 21:192-197.
36. Saito, H., H. Ebinuma, M. Oda, H. Ishii, et al. 1997. Results of the multicenter natural interferon-alpha treatment for chronic hepatitis C: correlation between total dose, administration periods and efficacy of therapy. Keio J. Med. 46:177-183.
37. Saito, H., H. Ebinuma, I. Satoh, S. Miyaguchi, S. Tada, N. Iwabuchi, N. Kumagai, K. Tsuchimoto, T. Morizane, and H. Ishii. 2000. Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J. Viral Hepat. 7:64-74.
38. Saito, H., S. Tada, N. Nakamoto, K. Kitamura, H. Horikawa, S. Kurita, Y. Saito, H. Iwai, and H. Ishii. 2004. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol. Res. 29:97-103.
39. Saito, H., K. Tsuchimoto, S. Miyaguchi, S. Tada, K. Sawaguchi, K. Komatsu, K. Kaneko, T. Watanabe, T. Morizane, H. Ishii, et al. 1996. Keio multicenter trial in high-dose interferon-alpha 2b treatment for chronic hepatitis C. Keio J. Med. 45:161-167.
40. Schalm, S. W., O. Weiland, B. E. Hansen, M. Milella, M. Y. Lai, A. Hollander, P. P. Michielsen, A. Bellobuono, L. Chemello, G. Pastore, D. S. Chen, J. T. Brouwer, et al. 1999. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 117:408-413.
41. Scott, L. J., and C. M. Perry. 2002. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 62:507-556.
42. Strader, D. B., T. Wright, D. L. Thomas, and L. B. Seeff. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171.
43. Sulkowski, M. S., R. Wasserman, L. Brooks, L. Ball, and R. Gish. 2004. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J. Viral Hepat. 11:243-250.
44. Tong, M. J., N. S. el-Farra, A. R. Reikes, and R. L. Co. 1995. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1463-1466.
45. Toyota, J., Y. Karino, J. Akaike, T. Ohmura, T. Sato, K. Yamazaki, Y. Kuwata, and S. Iino. 2005. Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon a plus ribavirin combination therapy. Kanzo 46:107-118. (In Japanese.)
46. Tsubota, A., N. Akuta, F. Suzuki, Y. Suzuki, T. Someya, M. Kobayashi, Y. Arase, S. Saitoh, K. Ikeda, and H. Kumada. 2002. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 45:33-42.
47. Tsubota, A., Y. Hirose, N. Izumi, and H. Kumada. 2003. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br. J. Clin. Pharmacol. 55:360-367.
48. Tsubota, A., F. Suzuki, K. Arase, M. Matsuda, M. Kobayashi, J. Sato, K. Takagi, S. Saito, Y. Suzuki, T. Someya, N. Kaida, M. Kobayashi, K. Ikeda, and M. Kumada. 2002. Efficacy of a newly developed measuring system for serum ribavirin concentration (HPLC assay). Kanzo 43:212-213. (In Japanese.)